Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests eltrombopag safety in kids with rare bone marrow failure

NCT ID NCT06287268

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 10 children aged 6 to 17 with aplastic anemia, a condition where the bone marrow stops making enough blood cells. The children are receiving eltrombopag (Revolade) for the first time, combined with anti-thymocyte globulin. Researchers are monitoring for serious side effects and how well the drug works, aiming to confirm its safety and effectiveness in this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

eltrombopag (Revolade)

What this could lead to

If successful, this could confirm that eltrombopag is safe and effective for treating aplastic anemia in children who haven't had prior immune-suppressing therapy.

What could go wrong

This is a small, observational study with only 10 participants, so results may not apply broadly. It is not designed to prove a cure, and risks like serious side effects are being monitored.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Nagoya, Aichi-ken, 453-8511, Japan

  • Novartis Investigative Site

    RECRUITING

    Nagoya, Aichi-ken, 4668560, Japan

  • Novartis Investigative Site

    RECRUITING

    Toyoake, Aichi-ken, 4701192, Japan

  • Novartis Investigative Site

    RECRUITING

    Chiba, Chiba, 260 8677, Japan

  • Novartis Investigative Site

    RECRUITING

    Amagasaki, Hyōgo, 660 8550, Japan

  • Novartis Investigative Site

    RECRUITING

    Kobe, Hyōgo, 6500047, Japan

  • Novartis Investigative Site

    RECRUITING

    Matsumoto, Nagano, 3908621, Japan

  • Novartis Investigative Site

    RECRUITING

    Shimajiri-Gun, Okinawa, 901-1303, Japan

  • Novartis Investigative Site

    RECRUITING

    Izumi, Osaka, 5941101, Japan

  • Novartis Investigative Site

    RECRUITING

    Osaka, Osaka, 5340021, Japan

  • Novartis Investigative Site

    RECRUITING

    Sakai, Osaka, 590-0197, Japan

  • Novartis Investigative Site

    RECRUITING

    Saitama, Saitama, 3308777, Japan

  • Novartis Investigative Site

    RECRUITING

    Ohtsu, Shiga, 5202192, Japan

  • Novartis Investigative Site

    RECRUITING

    Chuo Ku, Tokyo, 1048560, Japan

  • Novartis Investigative Site

    RECRUITING

    Ōta-ku, Tokyo, 143 8541, Japan

  • Novartis Investigative Site

    RECRUITING

    Setagaya-ku, Tokyo, 1578535, Japan

  • Novartis Investigative Site

    RECRUITING

    Wakayama, Wakayama, 641-8510, Japan